Aside from the expected inhibition of BTK, ibrutinib also inhibits multiple off-target kinases such as epidermal growth factor receptor (EGFR), ErbB2, interleukin-2-induced T-cell kinase (ITK), and the tyrosine kinase expressed in hepatocellular carcinoma (TEC), thus imparting a profile of toxicities (Jiang et al., 2024). Here, ITK is linked to hepatocellular carcinoma.